
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Keywords: osteoporosis; prostatic neoplasms; selective estrogen receptor modulators; toremifene; ADT; androgen deprivation therapy; AE; adverse event; BMD; bone mineral density; GnRH; gonadotropin-releasing hormone; HDL; high-density lipoprotein; LDL; low-density l